BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 27020305)

  • 1. Part 2. Notch-sparing γ-secretase inhibitors: The study of novel γ-amino naphthyl alcohols.
    Wei HX; Lu D; Sun V; Zhang J; Gu Y; Osenkowski P; Ye W; Selkoe DJ; Wolfe MS; Augelli-Szafran CE
    Bioorg Med Chem Lett; 2016 May; 26(9):2133-7. PubMed ID: 27020305
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Part 1: Notch-sparing γ-secretase inhibitors: The identification of novel naphthyl and benzofuranyl amide analogs.
    Lu D; Wei HX; Zhang J; Gu Y; Osenkowski P; Ye W; Selkoe DJ; Wolfe MS; Augelli-Szafran CE
    Bioorg Med Chem Lett; 2016 May; 26(9):2129-32. PubMed ID: 27013392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Part 3: Notch-sparing γ-secretase inhibitors: SAR studies of 2-substituted aminopyridopyrimidinones.
    Zhang J; Lu D; Wei HX; Gu Y; Selkoe DJ; Wolfe MS; Augelli-Szafran CE
    Bioorg Med Chem Lett; 2016 May; 26(9):2138-41. PubMed ID: 27038496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. (S)-N-(5-Chlorothiophene-2-sulfonyl)-beta,beta-diethylalaninol a Notch-1-sparing gamma-secretase inhibitor.
    Cole DC; Stock JR; Kreft AF; Antane M; Aschmies SH; Atchison KP; Casebier DS; Comery TA; Diamantidis G; Ellingboe JW; Harrison BL; Hu Y; Jin M; Kubrak DM; Lu P; Mann CW; Martone RL; Moore WJ; Oganesian A; Riddell DR; Sonnenberg-Reines J; Sun SC; Wagner E; Wang Z; Woller KR; Xu Z; Zhou H; Jacobsen JS
    Bioorg Med Chem Lett; 2009 Feb; 19(3):926-9. PubMed ID: 19097890
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proton myo-inositol cotransporter is a novel γ-secretase associated protein that regulates Aβ production without affecting Notch cleavage.
    Teranishi Y; Inoue M; Yamamoto NG; Kihara T; Wiehager B; Ishikawa T; Winblad B; Schedin-Weiss S; Frykman S; Tjernberg LO
    FEBS J; 2015 Sep; 282(17):3438-51. PubMed ID: 26094765
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantification of gamma-secretase modulation differentiates inhibitor compound selectivity between two substrates Notch and amyloid precursor protein.
    Yang T; Arslanova D; Gu Y; Augelli-Szafran C; Xia W
    Mol Brain; 2008 Nov; 1():15. PubMed ID: 18983676
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Difluoro ketone peptidomimetics suggest a large S1 pocket for Alzheimer's gamma-secretase: implications for inhibitor design.
    Moore CL; Leatherwood DD; Diehl TS; Selkoe DJ; Wolfe MS
    J Med Chem; 2000 Sep; 43(18):3434-42. PubMed ID: 10978191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TASTPM mice expressing amyloid precursor protein and presenilin-1 mutant transgenes are sensitive to γ-secretase modulation and amyloid-β₄₂ lowering by GSM-10h.
    Hussain I; Harrison DC; Hawkins J; Chapman T; Marshall I; Facci L; Ahmed S; Brackenborough K; Skaper SD; Mead TL; Smith BB; Giblin GM; Hall A; Gonzalez MI; Richardson JC
    Neurodegener Dis; 2011; 8(1-2):15-24. PubMed ID: 20689247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phenotypic approach to the discovery of compounds that promote non-amyloidogenic processing of the amyloid precursor protein: Toward a new profile of indirect β-secretase inhibitors.
    Gay M; Evrard C; Descamps F; Carato P; Renault N; Coevoet M; Eddarkaoui S; Baud C; Larchanché PE; Buée L; El Bakali J; Vingtdeux V; Sergeant N; Melnyk P
    Eur J Med Chem; 2018 Nov; 159():104-125. PubMed ID: 30268822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. gamma-Secretase as a therapeutic target in Alzheimer's disease.
    Guardia-Laguarta C; Pera M; Lleó A
    Curr Drug Targets; 2010 Apr; 11(4):506-17. PubMed ID: 20015011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of notch-sparing gamma-secretase inhibitors.
    Augelli-Szafran CE; Wei HX; Lu D; Zhang J; Gu Y; Yang T; Osenkowski P; Ye W; Wolfe MS
    Curr Alzheimer Res; 2010 May; 7(3):207-9. PubMed ID: 20088802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Begacestat (GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein gamma-secretase for the treatment of Alzheimer's disease.
    Martone RL; Zhou H; Atchison K; Comery T; Xu JZ; Huang X; Gong X; Jin M; Kreft A; Harrison B; Mayer SC; Aschmies S; Gonzales C; Zaleska MM; Riddell DR; Wagner E; Lu P; Sun SC; Sonnenberg-Reines J; Oganesian A; Adkins K; Leach MW; Clarke DW; Huryn D; Abou-Gharbia M; Magolda R; Bard J; Frick G; Raje S; Forlow SB; Balliet C; Burczynski ME; Reinhart PH; Wan HI; Pangalos MN; Jacobsen JS
    J Pharmacol Exp Ther; 2009 Nov; 331(2):598-608. PubMed ID: 19671883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological analysis of Drosophila melanogaster gamma-secretase with respect to differential proteolysis of Notch and APP.
    Groth C; Alvord WG; Quiñones OA; Fortini ME
    Mol Pharmacol; 2010 Apr; 77(4):567-74. PubMed ID: 20064975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aspartate mutations in presenilin and gamma-secretase inhibitors both impair notch1 proteolysis and nuclear translocation with relative preservation of notch1 signaling.
    Berezovska O; Jack C; McLean P; Aster JC; Hicks C; Xia W; Wolfe MS; Kimberly WT; Weinmaster G; Selkoe DJ; Hyman BT
    J Neurochem; 2000 Aug; 75(2):583-93. PubMed ID: 10899933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The novel gamma secretase inhibitor N-[cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexyl]-1,1,1-trifluoromethanesulfonamide (MRK-560) reduces amyloid plaque deposition without evidence of notch-related pathology in the Tg2576 mouse.
    Best JD; Smith DW; Reilly MA; O'Donnell R; Lewis HD; Ellis S; Wilkie N; Rosahl TW; Laroque PA; Boussiquet-Leroux C; Churcher I; Atack JR; Harrison T; Shearman MS
    J Pharmacol Exp Ther; 2007 Feb; 320(2):552-8. PubMed ID: 17099072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dynamics of {beta}-amyloid reductions in brain, cerebrospinal fluid, and plasma of {beta}-amyloid precursor protein transgenic mice treated with a {gamma}-secretase inhibitor.
    Barten DM; Guss VL; Corsa JA; Loo A; Hansel SB; Zheng M; Munoz B; Srinivasan K; Wang B; Robertson BJ; Polson CT; Wang J; Roberts SB; Hendrick JP; Anderson JJ; Loy JK; Denton R; Verdoorn TA; Smith DW; Felsenstein KM
    J Pharmacol Exp Ther; 2005 Feb; 312(2):635-43. PubMed ID: 15452193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Γ-secretase modulators do not induce Aβ-rebound and accumulation of β-C-terminal fragment.
    Li T; Huang Y; Jin S; Ye L; Rong N; Yang X; Ding Y; Cheng Z; Zhang J; Wan Z; Harrison DC; Hussain I; Hall A; Lee DH; Lau LF; Matsuoka Y
    J Neurochem; 2012 Apr; 121(2):277-86. PubMed ID: 22035227
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amino-caprolactam γ-secretase inhibitors showing potential for the treatment of Alzheimer's disease.
    Neitzel ML; Aubele DL; Marugg JL; Jagodzinski JJ; Konradi AW; Pleiss MA; Szoke B; Zmolek W; Goldbach E; Quinn KP; Sauer JM; Brigham EF; Wallace W; Bova MP; Hemphill S; Basi G
    Bioorg Med Chem Lett; 2011 Jun; 21(12):3715-20. PubMed ID: 21571529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Catalytic site-directed gamma-secretase complex inhibitors do not discriminate pharmacologically between Notch S3 and beta-APP cleavages.
    Lewis HD; Pérez Revuelta BI; Nadin A; Neduvelil JG; Harrison T; Pollack SJ; Shearman MS
    Biochemistry; 2003 Jun; 42(24):7580-6. PubMed ID: 12809514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological and Toxicological Properties of the Potent Oral
    Wagner SL; Rynearson KD; Duddy SK; Zhang C; Nguyen PD; Becker A; Vo U; Masliah D; Monte L; Klee JB; Echmalian CM; Xia W; Quinti L; Johnson G; Lin JH; Kim DY; Mobley WC; Rissman RA; Tanzi RE
    J Pharmacol Exp Ther; 2017 Jul; 362(1):31-44. PubMed ID: 28416568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.